Results 91 to 100 of about 9,605 (202)

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023

Global Health Research and Policy
Background The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level.
Qiyou Wu, Zhitao Wang, Yihan Fu, Ren Luo, Jing Sun   +4 more
doaj   +1 more source

Moving beyond a legacy paradigm: A vision for equitable access to quality medicines in Africa

International Journal of Gynecology &Obstetrics, Volume 172, Issue S2, Page S44-S50, June 2026.
Abstract Ensuring the availability of quality medicines is fundamental to achieving health outcomes and safeguarding public health. However, in many low‐ and middle‐income countries, especially across Africa, the current quality assurance paradigm—largely driven by historical donor preferences for WHO prequalification and stringent regulatory authority
Naoko Doi, Bright C. Orji, Michael Ruffo, Philippe Mukumbayi, Samuel Kibonge, Michael Mwiti Muthamia, Hannah Tappis, Franck Biayi, Talatu Y. Kassim, Albert Ndwiga   +9 more
wiley   +1 more source

Biosimilar medicines: creating sustainable competition in an era of a new patent cliff in biological medicines

Journal of Pharmaceutical Policy and Practice, 2015
Maarten Van Baelen
doaj   +1 more source

Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review

ClinicoEconomics and Outcomes Research
Grace E Fox,1 Mark Bernauer,1 Jennifer M Stephens,1 Bianca Jackson,1 Joshua A Roth,2 Ahmed Shelbaya2,3 1Strategic Market Access, OPEN Health, Bethesda, MD, USA; 2Global Access and Value, Pfizer Inc., New York, NY, USA; 3Department of Epidemiology ...
Fox GE, Bernauer M, Stephens JM, Jackson B, Roth JA, Shelbaya A   +5 more
doaj  

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

The Longer‐Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population‐Based Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background and Aims In 2019, British Columbia (BC) became the first jurisdiction in North America to introduce a mandatory non‐medical switching (NMS) policy requiring patients with Crohn's disease (CD) and ulcerative colitis (UC) to be switched from originator biologics to biosimilar equivalents.
Mark Harrison, Sandra Blitz, Michael Law, Mina Tadrous, Tara Gomes, Fiona Clement, Greg Rosenfeld, Aslam Anis, Nick Bansback   +8 more
wiley   +1 more source

A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany

International Journal of Women's Health, 2019
Weiguang Xue,1 Adam Lloyd,1 Edel Falla,1 Claudia Roeder,2 Rudiger Papsch,2 Klaus Bühler3,41IQVIA, Real-World Evidence, London, UK; 2Merck KGaA, Frankfurt, Germany; 3Centre for Gynecology Endocrinology & Reproductive Medicine Kinderwunsch-Zentrum
Xue W, Lloyd A, Falla E, Roeder C, Papsch R, Bühler K   +5 more
doaj  

Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease

BMC Health Services Research
Background Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies ...
Kerry A. Ryan, Shirley Cohen-Mekelburg, Jessica A. Baker, Eileen M. Weinheimer-Haus, Chris Krenz, Jason K. Hou, Raymond De Vries, Akbar K. Waljee   +7 more
doaj   +1 more source

A Case for Anti‐IgE Vaccination

Allergy, Volume 81, Issue 6, Page 2001-2013, June 2026.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source